AuntMinnie

MARCH 7, 2024

In 2023 compared with 2022, the total volume of positron emission tomography (PET) scans increased 10.2% year over year, according to the newly published IMV 2024 PET Market Summary Report. In 2023, the average number of PET scans per fixed PET site (versus mobile PET) increased 6.7%

PET Scan 115

PET Scan Nuclear Medicine Radiation Oncology Radiopharmaceuticals 115

AuntMinnie

FEBRUARY 12, 2024

Chinese clinicians have provided evidence in a “real-world study” that shows amyloid PET imaging is effective for diagnosing and managing patients with Alzheimer’s disease, according to a study published February 8 in Alzheimer’s and Dementia. The clinical utility of amyloid PET scans has been systematically studied in many other countries.

PET Scan 100

PET Scan Disease Diagnose Radiopharmaceuticals 100

Imaging Technology

APRIL 28, 2023

Because of the relatively short half-lives of PET radioisotopes, they must be created within hours of the patient’s scan. This collaboration will drive continuous innovation in molecular imaging agent production to improve access to radiopharmaceuticals in South Africa and help drive precision care in the region.”

Healthcare 85

Healthcare Healthcare Radiopharmaceuticals PET Scan 85

AuntMinnie

JANUARY 19, 2024

Reimbursement barriers Unfortunately, until recently, there were significant barriers to receiving amyloid PET imaging in some regions. Centers for Medicare and Medicaid Services (CMS), for example, did not cover amyloid PET scans outside of clinical trials for Medicare beneficiaries and only covered one scan per patient’s lifetime.

Disease 52

Disease Medicare Imaging PET Scan 52

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52